Document is current
Any future updates will be listed below
-
Authors
Minguet, Susana https://orcid.org/0000-0001-8211-5538
Maus, Marcela V. https://orcid.org/0000-0002-7578-0393
Schamel, Wolfgang W. https://orcid.org/0000-0003-4496-3100
- License Information
-
More Information
Article History
Accepted: 9 September 2024
First Online: 21 October 2024
Competing interests
: S.M. and W.W.S. are patent holders on ‘Lck-binding motif in CD3e’ (European patent application number 20711971.0 and US patent application number 20230070126). M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital and the University of Pennsylvania (some licensed to Novartis); holds equity in 2Seventy Bio, Genocea, Oncternal and Neximmune; and serves on the board of directors of 2Seventy Bio. W.W.S. and M.V.M. have served as consultants for multiple companies involved in cell therapies. The interests of M.V.M. were reviewed and are managed by Massachusetts General Hospital, and Massachusetts General Brigham in accordance with their conflict-of-interest policies.
